Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities.

Introduction

Stevens-Johnson syndrome (SJS) is a dermatological condition with the more severe form being toxic epidermal necrolysis syndrome (TEN) or Lyell’s syndrome. These two syndromes are said to exist at the two ends of the spectrum of an adverse skin reaction occurring from severe epidermolysis [ 1 ]. They present as severe exfoliative reactions affecting mainly the skin and mucous membranes [ 1 ]. The characteristic clinical presentation includes mucocutaneous tenderness, hemorrhagic erosions, and erosion of the mucous membrane, erythematous macules, blisters and denuded skin occurring as a result of the severe separation of the epidermis from the dermis [ 2 ]. The Bastuji-Garin et al. criterium is used in the diagnosis of SJS/TEN in which patients are classified into three categories based on the degrees of skin detachment [ 2 ], while the international classification uses the affected body surface area (BSA); SJS involves lower than 10% of the BSA, while TEN affects greater than 30% of the BSA. The definition of SJS and TEN incorporates an overlap which shall be highlighted in Table 1 below. It has been shown that SJS and TEN have mortalities in the range of 10 to 50 percent [ 3 ].

SJS/TEN can present in any age group but occurs more frequently in women, HIV-Infected patients, and the elderly. The global incidence rate associated with TEN is low, estimated in 2005 between 0.4 and 1.2 or 1.3 per million persons yearly. An epidemiologic study of TEN in France gave a similar incidence of 1 to 1.3 cases/million/ annum [ 4 ]. However, as the years’ advance, the numbers of incidence seem to be increasing in other parts of the world. Literature shows a correlation between the incidence and increasing age. The incidence increases sharply with increasing age, as does the use of drugs with ageing [ 5 ]. Females are most commonly affected represented by a female-male ratio of 3:2. The average age of patients reported is between the ages of 46 and 63, while the proportion of females is estimated between 61.3% and 64.3%, respectively [ 4 ]. Reports have also been linked to patients with Human Immunodeficiency Virus (HIV)-1 infection, recipients of bone-marrow transplants and systemic lupus erythematosus (SLE) [ 5 ].

Drug hypersensitivity has been associated with relatively complex genetic factors, which have been studied in diverse populations as well as in a variety of ethnic background. Chung et al., demonstrated a uniquely strong correlation between drug hypersensitivity (Carbamazepine triggered SJS), ethnic background (Hans Chinese) and Human Leucocyte Antigen (HLA)-B*1502 [ 3 ]. This strong association resulted in a further investigation into a similar cohort of Hong Kong Han Chinese having severe adverse cutaneous reactions to anticonvulsant drugs [ 6 ].

In another study of a Thai population, the susceptibility of individuals with HLA-B*1502 to the anticonvulsant carbamazepine was confirmed [ 7 ]. However, a weak association between carbamazepine and HLA-B*1502 was only demonstrable in an Indian-based study. While no genetic correlation could be established in Europeans and Japanese [ 8 ][ 9 ].

To further corroborate this non-genetic association in Europeans, a large study (RegiSCAR) carried out an HLA-B genotype on patients who suffered severe adverse cutaneous reactions triggered carbamazepine, lamotrigine, sulfamethoxazole, allopurinol, and NSAIDs of oxicam-type regarded as high-risk drugs. The study showed that HLA-B*1502 is not a confirmatory marker for any of the studied high-risk drugs known to cause SJS/TEN, and hence cannot be authoritatively labelled the cause of pathology in Europeans [ 10 ][ 11 ]. Therefore, it can be concluded that for SJS/TEN in individuals exposed to Carbamazepine, “the genetic constellation of HLA-B*1502 is not a population independent marker” [ 6 ].

HLA-B*5801 is another genotype which has been highly correlated with SJS/TEN in Han Chinese patients exposed to allopurinol. The study showed a 100% correlation of allopurinol exposure to HLA -B*5801 positive genotype in patients who presented with the adverse drug reactions [ 12 ]. Subsequent studies further revealed a high correlation between HLA-B*5801 and SJS/TEN in Thai patients [ 7 ], Japanese patients [ 9 ], and too much lower degree patients of European descent (about 55% of cases) [ 11 ].

Epidermal necrosis that occurs as a part of the TEN disease process is mainly associated with massive keratinocyte apoptosis [ 4 ]. This is mediated by surface receptors such as tumour necrosis factor (TNF) receptor (Fas), and when coupled with the Fas ligand causes disassembly of DNA and cell death by the induction of apoptosis [ 7 ]. Cell death could also be modulated by death receptor-independent mechanisms that include the release granzyme-B and perforins from cytotoxic T lymphocytes, thus activating the caspase-dependent or caspase-independent mechanism [ 12 ].

Clinical Presentation

The initial presentation of SJS/TEN may include non-specific symptoms such as fever, discomfort with swallowing, and stinging eyes. Typically, the cutaneous manifestations of SJS/TEN are usually preceded by these non-specific symptoms [ 13 ] [ 14 ]. Early locations for skin involvement include the presternal truncal region, the face, and could also involve the palms and the soles. In about 90% of patients, there is involvement of the mucosa of the mouth, genital and/or gastrointestinal tracts visible as erythema and erosions [ 13 ] [ 14 ]. Other frequent presentations at the beginning of the pathology is eye related and this ranges from acute conjunctivitis, erythema, edema of the eyelid, ocular discharge and crusting, to corneal erosion, the formation of conjunctival membrane or pseudomembrane, and in severe cases, to corneal ulcerations, cicatrizing lesions, fornix shortening, and symblepharon [ 15 ] [ 16 ]. However, late complications of SJS/TEN cannot be predicted by the severity of acute ocular manifestations [ 17 ]. Erythematous and livid macules typify the morphology of early cutaneous lesions.

The second phase is characterised by the development of wide-spread areas of epidermal separation. If no epidermal separation is observed, it warrants more detailed skin examination during which a tangential mechanical pressure is exerted on many erythematous areas, called Nikolsky sign. If the mechanical pressure causes and epidermal detachment, Nikolsky sign is positive. However, Nikolsky sign is not only defined for SJS or TEN, as it can equally be positive in conditions like the autoimmune bullous cutaneous pathologies like the pemphigus vulgaris [ 15 ] which can be utilised as a distinguishing feature from a similar autoimmune condition, bullous pemphigoid.

A major prognostic factor is the degree of cutaneous involvement. The evaluation of the degree of skin involvement should only include the already detached necrotic skin or detachable skin, that is, those that are Nikolsky positive [ 17 ].

Magina and colleagues [ 16 ] reported the following presentations for the late phase of TEN: Cutaneous hypo and hyperpigmentation (62.5%), nail dystrophies (37.5%), and the rest being eye complications. In another study, Yip et al. reported late ocular complications in about 50% of patients with TEN and reported them by ranking them in decreasing frequencies; “severe ocular dryness (46% of cases), trichiasis (16%), symblepharon (14%), distichiasis (14%), visual loss (5%), entropion (5%), ankyloblepharon (2%), lagophthalmos (2%), and corneal ulceration (2%)” [ 18 ]. Hypertrophic scars have only been reported in a handful of patients [ 19 ]. Reports have shown that 73% of patients with acute phase mucosal involvement subsequently presented with long-term complications with mucosal sequelae involving the oral and oesophagal mucosa majorly, and to a lesser degree, the genital and pulmonary mucosa [ 20 ]. Similarly, a nine-patient SJS/TEN study showed seven of the patients presenting with either keratoconjunctivitis or xerostomia or both, with a resemblance to Sjogren-like syndrome [ 21 ]. Furthermore, another report revealed a patient with “Sjögren-like pluriglandular exocrine insufficiency”, which is also resulted in an impairment of the exocrine pancreas [ 22 ].

Drug etiologies associated with SJS and TEN

A major percentage of the disease is caused by medications, while the remaining is due to upper respiratory infections such as HIV [ 23 ], Hepatitis virus, Herpes virus, Mycoplasma pneumoniae [ 24 ] [ 25 ]. Others include malignancies, as well as idiopathic. A substantial number of medications have been implicated in the aetiology of SJS/TEN. This article has attempted to review as many as possible of the published reports. The table 2 below summarises some drug categories that have been implicated in the aetiology of SJS/TEN.

Antibiotics

Sulfonamides: Among the antibiotics, the most implicated high-risk cause of SJS/TEN are the sulfonamides especially Trimethoprim -Sulfamethoxazole which accounts for about 69% of cases. The other non-sulfonamide antibiotics are considered low risk [ 23 ] [ 24 ]. Figure 1 , is a female patient with adverse cutaneous reaction from Trimethoprim-Sulfamethoxazole prescribed for an upper respiratory tract infection.

Aminopenicillins: Aminopenicillins have been shown to be the most frequent causes of SJS when compared to the other antibiotics. This could be due to how frequently they are prescribed [ 25 ]. Amoxicillin/clavulanic acid (Co-amoxiclav) even resulted in SJS in an 18-month-old child treated post-caustic poisoning and esophagogastric necrosis [ 26 ].

Fluoroquinolones: Ciprofloxacin induced SJS in a patient treated for otitis media reported in Sweden. [ 27 ] Norfloxacin induced SJS may appear similar to pemphigus, hence making early diagnosis a bit difficult [ 28 ].

Tetracyclines: Doxycycline has been implicated in the aetiology of SJS in the systemic use of ophthalmologic eyelid and ocular surface disorders [ 29 ]. Minocycline has been shown to induce both SJS and concurrent bilateral Parotitis in a young boy [ 30 ].

Macrolides: Azithromycin has been shown to cause SJS after a five-day outpatient completion [ 31 ].

Cephalosporins: Cefotaxime has been implicated in causing SJS when administered to an elderly lady for treatment of upper urinary infection [ 32 ], likewise Cefepime [ 33 ].

Metronidazole: Metronidazole induced SJS tends to start off with neurological manifestations before mucocutaneous and skin eruptions. This is worth noting, as patients should be advised of the early symptoms to prevent this rare adverse effect [ 34 ].

Anticonvulsants

Phenytoin: There is a possible association between the HLA-B*1502 allele and phenytoin-induced SJS in Asian patients. This is still under review by the FDA. This could mean a possible genetic predisposition to getting SJS in certain populations as opposed to others [ 35 ].

Lamotrigine: A potential rare side effect of SJS/TEN has been implicated regardless of appropriate dosing and adjustments; Concurrent use with Valproic acid increases risk [ 36 ].

Carbamazepine: Increased frequency of its use for pain control has further increased its implication in causing SJS/TEN [ 37 ].

Oxcarbazepine: A case was reported in India after use for treatment of epilepsy in a 21 – year-old male. SJS occurred 2 weeks during treatment despite accurate titrations [ 38 ].

Phenobarbital: Risk increases within the first 2 months of treatment. Genetic predisposition has been associated with this medication in conjunction with SJS/TEN [ 39 ].

Sodium valproate: A potential cause of SJS/TEN, though lower risk than the rest of the anticonvulsants. Increased risk when used together with other anticonvulsants. When used as monotherapy, it rarely causes SJS. However, if it occurs, it seems to be restricted to the involvement of only the oral mucosa [ 40 ].

Levetiracetam: It has been implicated in hypersensitivity syndrome reactions as well as SJS. Although rare it can be probably dose related [ 41 ].

Sulfonylureas

Glipizide: A study showed the increase in dosage from 5mg to 10 mg in a certain patient triggered a complex immune reaction that resulted in SJS the following day, it was postulated it could be due to the certain delayed immune reaction and possibly due to hapten hypothesis [ 42 ].

Diuretics

Furosemide: A potential adverse effect is SJS, especially when used as an additive with other sulfa-containing drugs [ 43 ].

Acetazolamide: A commonly used drug in ophthalmology. It is also a sulfonamide as well as a carbonic anhydrase inhibitor. It’s been associated with fatal SJS in patients of Korean and Japanese descents. HLA-B59, which is specific to Japanese descents, is a risk factor [ 44 ].

Analgesics

i) Non-steroidal anti-inflammatory drugs (NSAIDS):

Diclofenac: It could cause SJS especially in the elderly; caution should be applied when prescribing this drug [ 45 ].

Ibuprofen: SJS occurred in a Nepali male after taking 400mg of Ibuprofen every 8 hours for 2days. It could be due to genetic predisposition by HLA type or some inflammatory mediators causing epithelial damage [ 46 ].

Rofecoxib: A selective COX-2 inhibitor that has decreased gastrointestinal side effects was shown to cause SJS after three weeks of administration to a patient with systemic arthralgia [ 47 ].

ii) Paracetamol (Acetaminophen):

Paracetamol was shown to cause SJS/TEN despite its fair safety margin. It was shown to be dose-dependent in causing SJS [ 48 ].

Antidepressants

Mirtazapine: A patient with Systemic lupus erythematosus (SLE) who took mirtazapine for depression presented with SJS after 15 days of use. Though a very rare cause of SJS. The presence of the autoimmune disease led to a dilemma between either SLE or mirtazapine as the cause. The history and resolution of the disease eventually pointed to Mirtazapine as the culprit [ 49 ].

Duloxetine: The study showed 0.01% of patients treated with this medication could potentially cause SJS. An adolescent was affected in this study; so far it had only been adults involved [ 50 ].

Tyrosine kinase inhibitors

Afatinib: SJS can be seen in patients treated with Afatinib for Non-small cell lung cancer (NSCLC) [ 51 ].

Vandetanib: Also used in the treatment of NSCLC, was shown to cause SJS in certain patients [ 52 ].

Imatinib: SJS occurred in a patient treated with Imatinib for chronic myeloid leukaemia after treatment for 2 days. Caution should be taken in the prescription of this medication, as SJS is a potential adverse effect [ 53 ].

Sunitinib: A patient was treated with Sunitib for renal cell carcinoma with metastasis to the lung. On day 14 of treatment, the patient presented with SJS [ 54 ].

Xanthine oxidase inhibitor

Allopurinol: Commonly used in the treatment of chronic gout. It is usually considered a safe drug, and due to its frequent administration, increased risk for SJS/TEN is possible, also common in genetically predisposed patients especially in the Han Chinese population [ 55 ].

Androgenic hormones

Danazol: A patient diagnosed with systemic lupus erythematosus was prescribed danazol for treatment of autoimmune hemolytic anaemia. It has been approved as a second line agent in SLE related haematological disorders including thrombocytopenia [ 56 ].

Androgenic anabolic steroids: An athlete involved in the illicit use of steroids presented with SJS immediately after injecting drostanolone propionate, danazol, and metenolone enanthate [ 57 ]. Considering the common use of steroids for body performance, patients should be alerted to this rare side effect.

Antineoplastic drugs

Paclitaxel: An antineoplastic agent used to treat several cancers; Though SJS could be a rare complication, caution is advised when prescribed. A 53 – year-old male treated with Paclitaxel manifested symptoms after administration of second dose [ 58 ].

Docetaxel: Due to its strong toxicity, a patient presented with SJS after its use as a chemotherapeutic agent. Skin eruptions erupted after the first cycle of chemotherapy [ 59 ].

Tegafur/gimeracil/uracil (TS-1): A 78-year-old Japanese male presented with SJS eight days after treatment for carcinoma of the oral floor. Further tests showed an association between drug eruptions and antinuclear antibodies and positive drug-induced lymphocyte stimulation test [DLST] [ 60 ].

Anti viral drugs

i) Neuraminidase inhibitor (Oseltamivir); the medication is popularly known as Tamiflu and is indicated for prevention and treatment of Influenza. Considering the increased use of this drug, there are concerns about an increased risk for SJS [ 61 ]. ii) Nucleoside reverse transcriptase inhibitor (Adefovir): Commonly used in the treatment of Hepatitis B and Herpes simplex virus. A case of SJS was reported due to adefovir use [ 62 ]. iii) Non-nucleoside reverse transcriptase inhibitor (Nevirapine): Commonly used in the combination treatment for HIV. Patients infected with HIV-1 are more prone to SJS [ 63 ]. Figure 2 shows a healing adverse cutaneous reaction from Nevirapine (a component of the HAART) for a patient diagnosed with HIV. Figure 2 Patient with SJS/TEN caused by Nevirapine responding to therapy

Aggrenox

This is a combination of Aspirin and Dipyridamole, it is mainly used for stroke reduction in high-risk patients. It caused SJS in an elderly Chinese woman with transient ischemic attack who was recently switched from aspirin to Aggrenox [ 64 ].

Immunosuppressants/immunomodulators

i) Immuno-modulatory imide drugs (IMiDs):

Thalidomide: This is approved for use in the treatment of multiple myeloma. It inhibits Interleukin 6 (IL-6), a vital component in the proliferation of myeloma cells. A study once showed thalidomide could be used to treat SJS/TENS. However a case of SJS was reported with its use. This contradiction is worth noting [ 65 ].

Lenalidomide: Though similar to thalidomide, it has shown to have lesser adverse effects. A rare adverse effect is SJS [ 66 ].

ii) Imidazole nucleoside:

Mizoribine: An immunosuppressant used in renal transplants, lupus nephritis and rheumatoid arthritis. A 32-year-old Japanese woman diagnosed with SLE was started on mizoribine for lupus nephritis. She desired pregnancy hence cyclophosphamide was not used. Mizoribine induced SJS 6 months later despite its known safety margin [ 67 ].

Antihistamines

Fexofenadine: Telfast-D a drug containing both fexofenadine-pseudoephedrine was prescribed to a patient due to unrelenting allergic rhinitis. It further resulted in SJS. It was confirmed by skin testing (prick, intradermal and patch) which showed a positive reaction 96 hours later [ 68 ].

Angiotensin-converting enzyme inhibitors

Ramipril: Ramipril resulted in SJS after being newly prescribed for a patient for hypertension. ACE inhibitors are known to interfere directly with cell cohesion causing bullous eruptions, which are similar to pemphigus vulgaris or bullous pemphigoid. These reactions are usually non-immunological [ 69 ].

Antiosteoporotic agent

Strontium ranelate: It is known as a dual action bone agent (DABA) because of increases deposition of bone by osteoblasts and decreases resorption of bone by osteoclasts. A 67-year-old Chinese woman was diagnosed with SJS 3 weeks after starting this medication for treatment of post-menopausal osteoporosis [ 70 ].

Other reported non-therapeutic agents/chemicals in the aetiology of SJS

Iopentol: This is a contrast medium. A 6year old diagnosed with Hodgkin’s disease was injected with iopentol to undergo CT scan to explore his lymphadenopathy. Three days later he presented with SJS [ 71 ]. Knowing how common CT scans are used, it is worth noting the potential adverse effect of contrast medium.

Carbamate: This is an insecticide. A 63 – year-old farmer was exposed to the insecticide two days before presenting with SJS. He wasn’t on any medication. He admitted to contact of the carbamate with his skin [ 72 ]. There has been a reported case of TENS associated with oral ingestion of carbamate as a suicide attempt [ 73 ].

The therapeutic approach to SJS and TENS

The treatment modality employed in patient management is dependent on the aetiology of the disease which as previously mentioned could be; infectious, drug-induced, as well as malignancies or idiopathic [ 74 ].

The first step to the treatment of SJS and TENS is to eliminate the causative factor. In cases of SJS/TENS caused by infections with organisms, the patient is treated with the appropriate antimicrobial. For drug-induced SJS/TENS, the offending drug is withdrawn immediately [ 75 ].

The next step is the provision of supportive care for the patient. This includes administration of intravenous fluids as well as parenteral or nasogastric feeding. Patients are also to be kept in a warm environment [ 76 ].

The final step is symptomatic treatment. Several methods have been employed in symptomatic treatment ( Table 3 ).

Other potential therapeutic measures like the TNF-alpha inhibitor, thalidomide and Cyclophosphamide have been associated with increased mortality [ 77 ].

In conclusion, SJS and TEN are both life threatening adverse hypersensitivity reactions. Proper understanding of the etiology as well as the progression of these conditions is necessary for early diagnosis as well as treatment. It is expected that the investigation of the mechanism of action of drugs associated with SJS and TEN will improve the current understanding of the condition with aim of eliminating its incidence. There are existing treatment modalities for these conditions, however, there is no therapeutic measure defined as superior to others. It has however been observed that the earlier these conditions are diagnosed and managed the better the prognosis.

Authors Contribution

AOJ, PO, PA, FA, PE, DO and EO wrote the manuscript; AOJ and DO reviewed the manuscript; all the authors approved the manuscript for publication.

Acknowledgement

The authors wish to acknowledge the support of the administration of All Saints University School of Medicine, Dominica. The authors also appreciate the patients for giving their consent to use their pictures, though efforts were also made to ensure the privacy of their identity.

Funding: This research did not receive any financial support

Competing Interests: The authors have declared that no competing interests exist

References

1 Mockenhaupt M The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis Expert Rev Clin Immunol 2011 7 803 813 https://doi.org/10.1586/eci.11.66 PMid:22014021 22014021 10.1586/eci.11.66

2 Bastuji-Garin S Rzany B Stern RS Shear NH Naldi L Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme Arch Dermatol 1993 129 92 96 https://doi.org/10.1001/archderm.1993.01680220104023 8420497

3 Chung WH Hung SI Hong HS Hsih MS Yang LC Ho HC Wu JY Chen YT Medical genetics: a marker for Stevens-Johnson syndrome Nature 2004 428 486 https://doi.org/10.1038/428486a PMid:15057820 15057820 10.1038/428486a

4 Downey A Jackson C Harun N Cooper A Toxic epidermal necrolysis: Review of pathogenesis and management Journal of the American Academy of Dermatology 2012 66 6 995 1003 https://doi.org/10.1016/j.jaad.2011.09.029 PMid:22169256 22169256 10.1016/j.jaad.2011.09.029

5 Schwartz R McDonough P Lee B Toxic epidermal necrolysis Journal of the American Academy of Dermatology 2013 69 2 187 e1-187 e16 https://doi.org/10.1016/j.jaad.2013.05.002 PMid:23866879 23866879 10.1016/j.jaad.2013.05.002

6 Man CB Kwan P Baum L Yu E Lau KM Cheng AS Ng MH Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese Epilepsia 2007 48 1015 1018 https://doi.org/10.1111/j.1528-1167.2007.01022.x PMid:17509004 17509004 10.1111/j.1528-1167.2007.01022.x

7 Tassaneeyakul W Tiamkao S Jantararoungtong T Chen P Lin SY Chen WH Konyoung P Khunarkornsiri U Auvichayapat N Pavakul K Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population Epilepsia 2010 51 926 930 https://doi.org/10.1111/j.1528-1167.2010.02533.x PMid:20345939 20345939 10.1111/j.1528-1167.2010.02533.x

8 Alfirevic A Jorgensen AL Williamson PR Chadwick DW Park BK Pirmohamed M HLA-B locus in Caucasian patients with carbamazepine hypersensitivity Pharmacogenomics 2006 7 813 818 https://doi.org/10.2217/14622416.7.6.813 PMid:16981842 16981842 10.2217/14622416.7.6.813

9 Kaniwa N Saito Y Aihara M Matsunaga K Tohkin M Kurose K Sawada J Furuya H Takahashi Y Muramatsu M LA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis Pharmacogenomics 2008 9 1617 1622 https://doi.org/10.2217/14622416.9.11.1617 PMid:19018717 19018717 10.2217/14622416.9.11.1617

10 Lonjou C Thomas L Borot N Ledger N de Toma C LeLouet H Graf E Schumacher M Hovnanian A Mockenhaupt M Roujeau JC A marker for Stevens-Johnson syndrome: ethnicity matters Pharmacogenomics J 2006 6 265 268 https://doi.org/10.1038/sj.tpj.6500356 PMid:16415921 16415921 10.1038/sj.tpj.6500356

11 Lonjou C Borot N Sekula P Ledger N Thomas L Halevy S Naldi L Bouwes-Bavinck JN Sidoroff A de Toma C A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs Pharmacogenet Genomics 2008 18 99 107 https://doi.org/10.1097/FPC.0b013e3282f3ef9c PMid:18192896 18192896 10.1097/FPC.0b013e3282f3ef9c

12 Hung SI Chung WH Liou LB Chu CC Lin M Huang HP Lin YL Lan JL Yang LC Hong HS HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol Proc Natl Acad Sci USA 2005 102 4134 4139 https://doi.org/10.1073/pnas.0409500102 PMid:15743917 PMCid: PMC554812 15743917 10.1073/pnas.0409500102 PMC554812

13 Lebargy F Wolkenstein P Gisselbrecht M Lange F Fleury-Feith J Delclaux C Roupie E Revuz J Roujeau JC Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study Intensive Care Med 1997 23 1237 1244 https://doi.org/10.1007/s001340050492 9470079 10.1007/s001340050492 PMC7095164

14 Revuz J Penso D Roujeau JC Guillaume JC Payne CR Wechsler J Touraine R Toxic epidermal necrolysis Clinical findings and prognosis factors in 87 patients Arch Dermatol 1987 123 1160 1165 https://doi.org/10.1001/archderm.1987.01660330071012 PMid:3632000 3632000 10.1001/archderm.123.9.1160

15 Chang YS Huang FC Tseng SH Hsu CK Ho CL Sheu HM Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management Cornea 2007 26 123 129 https://doi.org/10.1097/ICO.0b013e31802eb264 PMid:17251797 17251797 10.1097/ICO.0b013e31802eb264

16 Sotozono C Ueta M Koizumi N Inatomi T Shirakata Y Ikezawa Z Hashimoto K Kinoshita S Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications Ophthalmology 2009 116 685 690 https://doi.org/10.1016/j.ophtha.2008.12.048 PMid:19243825 19243825 10.1016/j.ophtha.2008.12.048

17 Yip LW Thong BY Lim J Tan AW Wong HB Handa S Heng WJ Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series Allergy 2007 62 527 531 https://doi.org/10.1111/j.1398-9995.2006.01295.x PMid:17313402 17313402 10.1111/j.1398-9995.2006.01295.x

18 Magina S Lisboa C Leal V Palmares J Mesquita-Guimaraes J Dermatological and ophthalmological sequels in toxic epidermal necrolysis Dermatology 2003 207 33 36 https://doi.org/10.1159/000070938 PMid:12835545 12835545 10.1159/000070938

19 Sheridan RL Schulz JT Ryan CM Schnitzer JJ Lawlor D Driscoll DN Donelan MB Tompkins RG Long-term consequences of toxic epidermal necrolysis in children Pediatrics 2002 109 74 78 https://doi.org/10.1542/peds.109.1.74 11773544 10.1542/peds.109.1.74

20 Oplatek A Brown K Sen S Halerz M Supple K Gamelli RL Long-term follow-up of patients treated for toxic epidermal necrolysis J Burn Care Res 2006 27 26 33 https://doi.org/10.1097/01.bcr.0000194268.01514.f8 PMid:16566534 16566534 10.1097/01.bcr.0000194268.01514.f8

21 Roujeau JC Guillaume JC Revuz J Touraine R Reporting adverse drug reactions Lancet 1985 2 1244 10 https://doi.org/10.1016/S0140-6736(85)90771-8 10.1016/s0140-6736(85)90771-8 2866318

22 Saban J Pais JR Rodriguez JL Boixeda D Sjogren-like pluriglandular exocrine insufficiency after drug-induced toxic epidermal necrolysis Postgrad Med J 1991 67 195 197 https://doi.org/10.1136/pgmj.67.784.195 2041854 10.1136/pgmj.67.784.195 PMC2398994

23 Mockenhaupt M Viboud C Dunant A Naldi L Halevy S Bouwes Bavinck JN Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication riskswith emphasis on recently marketed drugs. The EuroSCAR study J Invest Dermatol 2008 128 35 44 https://doi.org/10.1038/sj.jid.5701033 PMid:17805350 17805350 10.1038/sj.jid.5701033

24 Rojeau JC Kelly JP Medication use and the risk of Steven Johnson syndrome or toxic epidermal necrolysis The New England Journal of Medicine 1995 333 1600 1608 https://doi.org/10.1056/NEJM199512143332404 PMid:7477195 7477195 10.1056/NEJM199512143332404

25 Ling YF Yang CH Severe cutaneous adverse reactions related to systemic antibiotics Clinical Infectious Diseases 2014 58 10 1377 1385 https://doi.org/10.1093/cid/ciu126 PMid:24599767 24599767 10.1093/cid/ciu126

26 Fatallah N Co-amoxiclav-induced Stevens Johnson Syndrome in a child Pan African Medical Journal 2013 14 38 https://doi.org/10.11604/pamj.2013.14.38.1408 23560121 10.11604/pamj.2013.14.38.1408 PMC3612873

27 Hallgren J Stevens-Johnson associated with ciprofloxacin: A review of adverse cutaneous events reported in Sweden associated with this drug J Am Acad Dermatol 2003 49 s267 9 https://doi.org/10.1016/S0190-9622(03)00478-X 14576649 10.1016/s0190-9622(03)00478-x

28 Maciejewska Stevens-Johnson syndrome/toxic epidermal necrolysis presumably induced by norfloxacin Postep Derm Alergol 2014 31 3 194 196 https://doi.org/10.5114/pdia.2014.40796 PMid:25097494 PMCid: PMC4112256 10.5114/pdia.2014.40796 PMC4112256 25097494

29 Lau B Mutyala D Dhaliwal D.A Case report of Doxycycline induced Steven Johnson syndrome Corneal Journal 2011 30 595 597 https://doi.org/10.1097/ICO.0b013e3181f05773 PMid:21099409 10.1097/ICO.0b013e3181f05773 21099409

30 Yoon J Lee SH Concurrence of stevens johnson syndrome and bilateral parotitis after minocycline therapy Case rep dermatol 2010 2 88 94 https://doi.org/10.1159/000314952 PMid:21103193 PMCid: PMC2988842 21103193 10.1159/000314952 PMC2988842

31 Nappe TM Steven Johnson syndrome after treatment with azithromycin An uncommon culprit. American journal of emergency medicine 2016 34 676e1 676e3 26194400 10.1016/j.ajem.2015.06.039

32 Liberopoulos E Possible Cefotaxime-Induced Stevens–Johnson Syndrome The Annals of Pharmacotherapy 2003 37 812 814 https://doi.org/10.1345/aph.1C453 PMid:12773067 12773067 10.1345/aph.1C453

33 Luciano M Stevens-Johnson syndrome caused by cefepime;Journal of Pharmacology and Pharmacotherapeutics 2015 2015 35 10.4103/0976-500X.149143 PMC4319247 25709351

34 Mazumdar Goutameswar Koushik Shome Stevens-Johnson syndrome following use of metronidazole in a dental patient Indian Journal of Pharmacology 2014 46 1 121 https://doi.org/10.4103/0253-7613.125193 PMid:24550598 PMCid: PMC3912796 24550598 10.4103/0253-7613.125193 PMC3912796

35 Hun YF Wu XT Phenytoin-induced Stevens–Johnson syndrome with negative HLA-B*1502 allele in mainland China: Two cases Elsevier seizure 2011 20 431 432 https://doi.org/10.1016/j.seizure.2011.01.005 PMid:21334226 10.1016/j.seizure.2011.01.005 21334226

36 Hilas O Charneski L Lamotrigine induced steven johnson syndrome Am J Health Syst Pharm 2007 64 273 275 https://doi.org/10.2146/ajhp060071 PMid:17244876 17244876 10.2146/ajhp060071

37 Devi K The commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: A study of 7 years Indian Journal of Dermatology, Venereology and Leprology 2005 71 5 325 https://doi.org/10.4103/0378-6323.16782 10.4103/0378-6323.16782 16394456

38 Sharma SR Sharma N Yeolekar ME Oxcarbazepine-induced Stevens Johnson syndrome: A rare case report Indian Dermatol Online J 2011 2 13 5 https://doi.org/10.4103/2229-5178.79861 PMid:23130207 PMCid: PMC3481788 23130207 10.4103/2229-5178.79861 PMC3481788

39 Gaur Sumit Rupali Agnihotri Phenobarbital induced Stevens-Johnson syndrome in a child Indian Journal of Pharmacology 2012 44 4 531 https://doi.org/10.4103/0253-7613.99344 PMid:23087523 PMCid: PMC3469965 23087523 10.4103/0253-7613.99344 PMC3469965

40 Naveen K Stevens-Johnson syndrome induced by sodium valproate monotherapy International Journal of Critical Illness and Injury Science 2012 2 1 44 https://doi.org/10.4103/2229-5151.94904 PMid:22624102 PMCid: PMC3354377 22624102 10.4103/2229-5151.94904 PMC3354377

41 Zou LP Ding CH Stevens Johnson syndrome induced by levetiracetam Elsevier Seizure 2012 21 823 825 https://doi.org/10.1016/j.seizure.2012.09.005 PMid:23036769 10.1016/j.seizure.2012.09.005 23036769

42 Cheng JB Anderson RC Stevens Johnson Syndrome associated with Glipizide Therapy Dermatitis 2006 17 1 36 38 https://doi.org/10.2310/6620.2006.05038 16800277 10.2310/6620.2006.05038

43 Wright AA Vesta K Stevens-Johnson Syndrome Associated With Furosemide: A Case Report Journal of Pharmacy practice 2010 23 4 367 370 https://doi.org/10.1177/0897190010362260 PMid:21507837 21507837 10.1177/0897190010362260

44 Her Y Stevens–Johnson syndrome induced by acetazolamide Journal of Dermatology 2011 38 272 275 https://doi.org/10.1111/j.1346-8138.2010.00921.x PMid:21342230 21342230 10.1111/j.1346-8138.2010.00921.x

45 Babamahmoodi F Eslami G Diclofenac-Induced Stevens-Johnson Syndrome: A Case Report Iranian journal of pharmacology & therapeutics 2012 11 33 35

46 Angadi S Karn A Ibuprofen induced Stevens-Johnson syndrome-toxic epidermal necrolysis in Nepal Asia Pac Allergy 2016 6 70 73 https://doi.org/10.5415/apallergy.2016.6.1.70 PMid:26844223 PMCid: PMC4731484 26844223 10.5415/apallergy.2016.6.1.70 PMC4731484

47 Goldberg D Panigrahi D A Case of Rofecoxib-Associated Stevens-Johnson syndrome With Corneal and Conjunctival Changes Cornea 2004 23 7 736 737 https://doi.org/10.1097/01.ico.0000126330.77228.a3 PMid:15448505 15448505 10.1097/01.ico.0000126330.77228.a3

48 Biswal S Sourav S Paracetamol induced Stevens-Johnson syndrome – toxic epidermal necrolysis overlap syndrome International journal of Dermatology 2014 53 1042 1044 https://doi.org/10.1111/ijd.12355 PMid:24673330 24673330 10.1111/ijd.12355

49 Bhasin A First case of mirtazepine-induced Stevens-Johnson syndrome from India;Indian Journal of Pharmacology 2012 44 5 656 https://doi.org/10.4103/0253-7613.100411 PMid:23112435 PMCid: PMC3480806 10.4103/0253-7613.100411 PMC3480806 23112435

50 Strawn J Whitsel R Atypical stevens Johnson syndrome in an adolescenttreated with duloxetine Journal of child and adolescent psychopharmacology 2011 21 91 92 https://doi.org/10.1089/cap.2010.0071 PMid:21309700 21309700 10.1089/cap.2010.0071

51 Doesch J Debus D Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient Elsevier. Lung Cancer 2016 95 35 38 https://doi.org/10.1016/j.lungcan.2016.02.015 PMid:27040849 10.1016/j.lungcan.2016.02.015 27040849

52 Yoon J Stevens-Johnson Syndrome Induced by Vandetanib Ann Dermatol 2011 23 Suppl. 3 S343 5 https://doi.org/10.5021/ad.2011.23.S3.S343 PMid:22346274 PMCid: PMC3276793 22346274 10.5021/ad.2011.23.S3.S343 PMC3276793

53 Jha P Himanshu D Jain N Singh AK Imatinib-induced Stevens-Johnsons syndrome BMJ case reports 2013 2013 bcr2012007926 10.1136/bcr-2012-007926 PMC3604560 23349042

54 Lee J Case of sunitinib-induced Stevens–Johnson syndrome.Journal of dermatology 2013 40 9 753 4 https://doi.org/10.1111/1346-8138.12219 PMid:23855706 10.1111/1346-8138.12219 23855706

55 Mockenhaupt M Allopurinol is the most frequent cause of Stevens-Johnson syndrome and toxic epidermal necrolysis Expert Review of Dermatology 2012 7 3 213 https://doi.org/10.1586/edm.12.5 10.1586/eci.11.66 22014021

56 Koh WL Tay YK Koh MJA Danazol-induced Stevens-Johnson syndrome in a patient with systemic lupus erythematosus Dermatology Online Journal 2015 21 1 17 25612133

57 Cocoa S Viviano M Stevens-Johnson syndrome and abuse of anabolic steroids J Korean Assoc Oral Maxillofac Surg 2017 43 57 60 https://doi.org/10.5125/jkaoms.2017.43.1.57 PMid:28280713 PMCid: PMC5342976 28280713 10.5125/jkaoms.2017.43.1.57 PMC5342976

58 Hiraki Stevens-Johnson Syndrome Induced by Paclitaxel in a Patient with Squamous Cell Carcinoma of the Lung Anticancer research 2004 24 1135 1138 PMid:15154637 15154637

59 Sawada Y Docetaxel-induced StevensJohnson syndrome with regenerating epidermis composed of atypical keratinocytes European Academy of Dermatology and Venereology 2009 23 1333 1334 https://doi.org/10.1111/j.1468-3083.2009.03183.x PMid:19453796 10.1111/j.1468-3083.2009.03183.x 19453796

60 Minakawa S Tegafur/gimeracil/oteracil (TS-1) induced StevenseJohnson syndrome Dermatologica Sinica 2013 31 154e156

61 Smith EV Pynn MC Blackford S Leopold DJ Stevens–Johnson syndrome secondary to oseltamivir (Tamiflu®) Br J Gen Pract 2010 60 571 133 4 https://doi.org/10.3399/bjgp10X483292 PMid:20132714 PMCid: PMC2814276 10.3399/bjgp10X483292 PMC2814276 20132714

62 Chattopadhyay P Sarma N Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome Singapore Med J 2011 52 2 31 34 21373727

63 Singh H Nevirapine induced Stevens-Johnson syndrome in an HIV infected patient Indian Journal of Pharmacology 2011 43 1 84 https://doi.org/10.4103/0253-7613.75680 PMid:21455432 PMCid: PMC3062132 21455432 10.4103/0253-7613.75680 PMC3062132

64 Jao T Aggrenox (Asasantin retard)-induced Stevens–Johnson syndrome British Journal of Clinical Pharmacology 2008 67 2 264 265 https://doi.org/10.1111/j.1365-2125.2008.03340.x PMid:19094159 PMCid: PMC2670386 19094159 10.1111/j.1365-2125.2008.03340.x PMC2670386

65 Das A Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma Indian Journal of Pharmacology 2014 46 5 557 https://doi.org/10.4103/0253-7613.140598 PMid:25298592 PMCid: PMC4175899 25298592 10.4103/0253-7613.140598 PMC4175899

66 Allegra A Alonci A Stevens–Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options Hematol Oncol 2012 30 41 45 https://doi.org/10.1002/hon.1000 PMid:21702057 21702057 10.1002/hon.1000

67 Kakushi M Atsuo O Stevens–Johnson syndrome induced by mizoribine in a patient with systemic lupus erythematosus, Modern Rheumatology 2006 16 2 113 116 https://doi.org/10.3109/s10165-006-0467-5 10.1007/s10165-006-0467-5 16633933

68 Teo SL Santosa A Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Induced by Fexofenadine J Investig Allergol Clin Immunol 2017 27 3 191 193 https://doi.org/10.18176/jiaci.0158 PMid:28570227 10.18176/jiaci.0158 28570227

69 Oskay T Stevens–Johnson Syndrome associated with Ramipril International Journal of Dermatology 2003 42 580 58 https://doi.org/10.1046/j.1365-4362.2003.01838.x PMid:12839617 12839617 10.1046/j.1365-4362.2003.01838.x

70 Tan KW Wang YS Tay YK Stevens-Johnson Syndrome Due to Strontium Ranelate Annals Academy of Medicine 2011 40 11 22206068

71 Lafitte E Severe Stevens–Johnson syndrome induced by contrast medium iopentol British Journal of Dermatology 2004 150 376 377 https://doi.org/10.1111/j.1365-2133.2003.05763.x 14996121 10.1111/j.1365-2133.2003.05763.x

72 Lim JH Stevens–Johnson syndrome following occupational exposure to carbamate insecticide Journal of Dermatology 2010 37 182 184 https://doi.org/10.1111/j.1346-8138.2009.00784.x PMid:20175856 20175856 10.1111/j.1346-8138.2009.00784.x

73 Rajendran N Chitfambalam PC Jayaraman AM Carbamate pesticide induced toxic epidermal necrolysis.Indian J Dermatol Venereol Leprol 2001 67 253 254 PMid:17664764 17664764

74 Zaidi M Amoxycillin and Clavulanic Acid Induced Stevens-Johnson Syndrome: A Case Report Excli Journal 2017 16 748 751 PMid:28827990 PMCid: PMC5547378 28827990 10.17179/excli2017-345 PMC5547378

75 Biswal S Sahoo SS Paracetamol induced Stevens?Johnson syndrome–toxic epidermal necrolysis overlap syndrome International journal of dermatology 2014 53 8 1042 4 https://doi.org/10.1111/ijd.12355 PMid:24673330 24673330 10.1111/ijd.12355

76 Bajwa SJ Kaur J Stevens–Johnsons syndrome and toxic epidermal necrolysis: Need to look beyond current etiologies, diagnostics, and therapeutics Medical Journal of Dr. DY Patil Vidyapeeth 2017 10 1 68 https://doi.org/10.4103/0975-2870.197913

77 Kohanim S Palioura S Saeed HN Akpek EK Amescua G Basu S Blomquist PH Bouchard CS Dart JK Gai X Gomes JA Stevens-Johnson syndrome/toxic epidermal necrolysis–a comprehensive review and guide to therapy I. Systemic disease. The ocular surface 2016 14 1 2 19 https://doi.org/10.1016/j.jtos.2015.10.002 PMid:26549248 26549248 10.1016/j.jtos.2015.10.002

78 Schneider J Cohen P Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures Advances in Therapy 2017 34 6 1235 1244 https://doi.org/10.1007/s12325-017-0530-y PMid:28439852 PMCid: PMC5487863 28439852 10.1007/s12325-017-0530-y PMC5487863

79 Maciejewska J Stevens-Johnson syndrome/Toxic epidermal necrolysis presumably induced by norfloxacin Advances in Dermatology and Allergology 2014 3 194 196 https://doi.org/10.5114/pdia.2014.40796 PMid:25097494 PMCid: PMC4112256 10.5114/pdia.2014.40796 PMC4112256 25097494

80 Allegra A Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options Hematological Oncology 2011 30 1 41 45 https://doi.org/10.1002/hon.1000 PMid:21702057 21702057 10.1002/hon.1000